Endocrine signaling research
IGF-1 LR3
Lyophilized endocrine-signaling research peptide for systems review
IGF-1 LR3 is a modified IGF-1 analog studied around IGF receptor signaling and altered binding-protein interaction.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
Research context
IGF-1 LR3 research profile
IGF-1 LR3 is a modified analog of insulin-like growth factor 1 designed with sequence changes that reduce interaction with IGF-binding proteins and alter experimental persistence. Cell and animal studies use it to examine IGF-1 receptor signaling, PI3K-AKT and MAPK pathways, proliferation, differentiation, glucose handling, and other growth-related endpoints. It is not interchangeable with endogenous IGF-1, full-length HGH, or upstream GH secretagogues. IGF-1 LR3 is generally selected for controlled cell-culture or receptor-pathway experiments that specifically require the long-R3 analog. Results can vary substantially with cell type, serum conditions, concentration, and exposure time, and the evidence base is primarily preclinical.
Proposed mechanism
A modified IGF-1 analog with an N-terminal extension and an amino-acid substitution that reduce affinity for IGF-binding proteins. The proposed result is greater free analog availability and prolonged activation of IGF-1R, PI3K-AKT, and MAPK signaling.
Effects reported in studies
- Cell studies report increased proliferation, survival signaling, differentiation, protein synthesis, and glucose uptake in responsive cell types.
- Animal and agricultural-model studies report growth and metabolic effects that vary with tissue, dose, and exposure.
- Prolonged mitogenic signaling, hypoglycemia-related effects, and uncontrolled cell growth are important experimental concerns.
Common research endpoints
IGF-1R phosphorylation, AKT and ERK signaling, proliferation, apoptosis, differentiation, protein synthesis, glucose uptake, binding-protein interaction, and exposure duration.
Evidence and limitations
Evidence is predominantly cell and animal based. IGF-1 LR3 is not equivalent to endogenous IGF-1, and established human safety data are lacking.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.